JSPR Form 4 reports purchase transactions

WIGGANS THOMAS G reported open-market purchase transactions in a Form 4 filing for JSPR.

Accepted by SEC EDGAR 09/24/2025 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

WIGGANS THOMAS G reported open-market purchase transactions in a Form 4 filing for JSPR. The filing lists transactions totaling 82,000 shares at a weighted average price of $2.43 per share. Following the reported transactions, holdings were 41,000 shares.

Insider Trade Summary

Net Buyer: 82,000 shares

Net Buy 2 txns

Insider WIGGANS THOMAS G

Role Director

Bought 82,000 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Common Stock Warrant (right to buy)	41,000	$0.00	$0.00
Purchase	Voting Common Stock	41,000	$2.43	$100K
Holding	Voting Common Stock	--	--	--

Holdings After Transaction: Common Stock Warrant (right to buy) — 41,000 contracts (Indirect, By Wiggans Living Trust); Voting Common Stock — 41,000 shares (Indirect, By Wiggans Living Trust); Voting Common Stock — 5,000 shares (Direct)

Footnotes (1)

1. F1. Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jasper Therapeutics (JSPR) report for Thomas G. Wiggans?

Jasper Therapeutics reported that the Wiggans Living Trust, associated with director Thomas G. Wiggans, bought 41,000 voting common shares and 41,000 related warrants on September 22, 2025. The transaction increased his indirect ownership in the company’s equity.

At what price did the Wiggans Living Trust buy Jasper Therapeutics (JSPR) shares and warrants?

Each voting common share was purchased with one warrant at a combined offering price of $2.43 per share and warrant. The warrants themselves have an exercise price of $2.92 per share, reflecting additional cost if they are later exercised into common stock.

How many Jasper Therapeutics (JSPR) warrants does the Wiggans Living Trust now hold?

Following the reported transaction, the Wiggans Living Trust beneficially owns 41,000 common stock warrants. Each warrant allows the purchase of one share of voting common stock between March 22, 2026 and March 22, 2030, subject to payment of the $2.92 exercise price.

When do the Jasper Therapeutics (JSPR) warrants acquired by the Wiggans Living Trust become exercisable?

The warrants acquired by the Wiggans Living Trust become exercisable on March 22, 2026 and expire on March 22, 2030. During this window, each warrant can be used to buy one voting common share at an exercise price of $2.92 per share.

Is the Wiggans Living Trust’s Jasper Therapeutics (JSPR) ownership direct or indirect?

The 41,000 voting common shares and 41,000 warrants are reported as indirectly owned through the Wiggans Living Trust. In addition, the filing shows Thomas G. Wiggans directly owning 5,000 voting common shares separate from the trust’s indirect holdings.

How were the Jasper Therapeutics (JSPR) shares and warrants acquired by the Wiggans Living Trust?

According to the filing, each voting common share was purchased together with a warrant in an underwritten public offering. Investors paid a combined offering price of $2.43 for each share of voting common stock and its accompanying warrant in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

WIGGANS THOMAS G

(Last) (First) (Middle)

C/O JASPER THERAPEUTICS, INC.

2200 BRIDGE PKWY, SUITE #102

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	09/22/2025		P		41,000	A	$2.43(1)	41,000	I	By Wiggans Living Trust
Voting Common Stock								5,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrant (right to buy)	$2.92	09/22/2025		P		41,000		03/22/2026	03/22/2030	Voting Common Stock	41,000	(1)	41,000	I	By Wiggans Living Trust

Explanation of Responses:

1. Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant.

	/s/ Herb Cross, as Attorney-in-Fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.